Navigation Links
Chantix And NuvaRing Lawsuit Funding Added To Pharmaceutical Drug List At Legal-Bay
Date:6/13/2013

SAN FRANCISCO, June 13, 2013 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that they are one of the first funding firms to offer plaintiffs of both Chantix and NuvaRing litigation's with lawsuit pre-settlement funding.  Legal-Bay is a leader in both product liability funding in case of recalled hip products and transvaginal mesh cases, as well as bad pharmaceutical drugs.  The addition to begin funding Chantix and NuvaRing indicates the company's intentions to be at the forefront of funding in mass tort cases. 

(Logo: http://photos.prnewswire.com/prnh/20130613/PH30672LOGO)

"We believe both the Chantix and NuvaRing litigation represent mass tort plaintiffs with serious side effects to the drugs and product taken.  Although most companies in the legal funding community believe these litigations still pose significant risk, we remain steadfast in our commitment to assist victims of Chantix and NuvaRing who need cash to pay for bills and live until their settlement is obtained", Said Chris Janish, CEO of Legal-Bay.  Legal-Bay's NuvaRing and Chantix funding products are not lawsuit loans, as there are no monthly payments and the funds only need to be paid back if you win your case.    

Chantix the smoking cessation drug has left many people with serious bouts of depression and ultimately suicidal actions in some cases.  NuvaRing was billed as an innovative birth control option for women, however the side effects to the product included heart attack, stroke, pulmonary embolisms and vein issues. 

Chantix and NuvaRing is in addition to the following bad pharmaceutical drugs that Legal-Bay is actively funding:

  • Accutane
  • Actos
  • Avandia
  • Gadolinum
  • Prempro/HRT
  • Vioxx
  • Yaz, Yasmin, and Ocella

Legal-Bay's "Big Pharma" funding list is constantly changing, so feel free to inquire about funding on a product that you do not see above. 

If you were injured by a Chantix, NuvaRing or another pharmaceutical drug and need a lawsuit cash advance, feel free to apply online at: http://lawsuitssettlementfunding.com or by calling Legal-Bay toll free at 877.571.0405 where live agents are always available to answer your Chantix or NuvaRing Lawsuit Funding questions.  (You must have a lawyer to apply for Chantix lawsuit funding, however if you need a Chantix lawyer or NuvaRing lawyer, feel free to contact Legal-Bay and they can provide you with an attorney who will give you a free legal consultation.)

Contact:  Patty Kirby, Head of Client Relations
              Ph. 877.571.0405   Email:  Info@legal-bay.com


'/>"/>
SOURCE Legal-Bay LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. RD Legal Offers Funding to Plaintiffs Attorneys with Chantix Settlements
2. Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit
3. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAG
4. Stryker And DePuy Pinnacle Hip Lawsuit Settlement News Update
5. The Law Offices of Marc S. Henzel Announces Class Action Lawsuit Against Aveo Pharmaceuticals, Inc. and Certain Officers -- (Nasdaq: AVEO) was filed on behalf of stockholders
6. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
7. Medstrat Posts Documents Confirming Terms Of Dismissal Of Merges Lawsuit
8. Vaginal Mesh Lawsuit Website Launched by Dr. Greg Vigna
9. Medifast, Inc. Announces Favorable Resolution of Securities Class Action Lawsuit
10. Star Scientific Responds to Plaintiffs Purported Class Action Lawsuit
11. OrbusNeich File Patent Infringement Lawsuit Against Boston Scientific in Ireland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):